Cancer

Sona Nanotech Closes Private Placement Financing to Raise $750,000 in Gross Proceeds and Announces Additional Financing

Halifax, Nova Scotia--(Newsfile Corp. - November 27, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…

1 year ago

Glioblastoma Foundation Hosts ‘Rock Against Glioblastoma’ (RAG), Shining a Spotlight on Deadliest Form of Brain Cancer

First Annual Music Festival Features Talented Lineup of Performers at the Legendary Cat's Cradle, Raising Vital Funds for Glioblastoma Research…

1 year ago

SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform

MitoCareX Bio has met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel,…

1 year ago

iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

New research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict…

1 year ago

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today…

1 year ago

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

Boca Raton, Florida, Nov. 27, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company…

1 year ago

RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

Positive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50,…

1 year ago

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and…

1 year ago

Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Anavex…

1 year ago